FDA 授予卫材治疗早期阿尔茨海默氏症的抗 tau 蛋白药物 etalanetug 与 lecanemab 配对的快速通道。 FDA grants Fast Track to Eisai’s anti-tau drug etalanetug for early Alzheimer’s, paired with lecanemab.

Eisai的实验性抗体抗体抗体抗体抗体抗体抗体试验针对与阿尔茨海默氏病蔓延有关的一特定部分Tau蛋白质,现已获得FDA快车道的指定,以加速其发展。 Eisai's experimental anti-tau antibody etalanetug, which targets a specific part of tau protein linked to Alzheimer's spread, has received FDA Fast Track designation to speed its development. 正在第二阶段对阿兹海默氏早期发作试验中测试该疗法,同时进行抗氨基甲状腺素治疗。 The therapy is being tested in Phase II trials for early-onset Alzheimer's, combined with lecanemab, an anti-amyloid treatment. " 快车道 " 方案支持更快地审查应对医疗需求未得到满足的严重状况的药物。 The Fast Track program supports faster review for drugs addressing serious conditions with unmet medical needs. Eisai以神经学为重点,旨在推进痴呆症和相关疾病的治疗。 Eisai, focusing on neurology, aims to advance treatments for dementia and related diseases.